EPIRUS Reports Fourth Quarter and Fiscal Year 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results

BOSTON, March 23, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS ), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.

"In 2014, we became a publicly listed company and a commercial-stage company with the launch of our lead product candidate, BOW015 , in our first market," stated Amit Munshi, President and Chief Executive Officer, EPIRUS Biopharmaceuticals . "I am pleased with the milestones achieved in 2014 and the momentum carried into 2015 as we move toward becoming a sustainable, profitable biosimilar business."

2014 Corporate Highlights

  • Infimab™ (BOW015 – biosimilar to Remicade®) Launched in First Market : In November, EPIRUS launched its first product, Infimab (BOW015), in India in collaboration with its commercialization partner, Ranbaxy Laboratories. The launch was one quarter ahead of schedule and signified not only the first product launch and approval for the Company, but also the first infliximab biosimilar in India. Remicade (infliximab) is currently marketed globally for the treatment of inflammatory diseases, including rheumatoid arthritis, Crohn's Disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis. Additional regulatory filings for BOW015 in targeted accessible markets are expected throughout 2015.
  • Positive 58 Week Data from Phase 3 BOW015 Trial : In November, EPIRUS presented positive data for its Phase 3 clinical trial in India at the American College of Rheumatology Annual Meeting. In the open label phase, it was demonstrated that patients can be safely initiated and effectively maintained on BOW015 for 58 weeks, and that patients can be safely switched from Remicade to BOW015 and effectively maintained out to 58 weeks. The Company intends to initiate a global clinical program for BOW015 in late 2015 / early 2016 to support regulatory filings in the US and EU.  
  • Livzon Collaboration Agreement : In September, EPIRUS entered into a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm Inc. (Livzon), a Chinese biotechnology company focused on the development, manufacturing and sale of antibody-based drugs. Livzon was the principal investor in the $36 million private financing round that EPIRUS completed in April 2014, prior to becoming a public company. Under the terms of the agreement, EPIRUS and Livzon will work together to develop, manufacture and commercialize up to five biosimilar products. The first collaboration product is BOW015. 
  • EPIRUS and Zalicus Merger : In July, EPIRUS completed a reverse stock-merger with Zalicus Inc. The combined enterprise was renamed EPIRUS Biopharmaceuticals, Inc., and began trading on Nasdaq under the symbol EPRS on July 16, 2014. 

Fourth Quarter 2014 Financial Highlights

  • Research and Development (R&D) expenses were $4.8 million for the fourth quarter of 2014 compared to $2.4 million for the fourth quarter of 2013, an increase of $2.4 million. This increase was primarily the result of development, manufacturing and commercialization expenses related to BOW015, as well as the advancement of other pipeline products.   
  • General and Administrative (G&A) expenses were $5.4 million for the fourth quarter of 2014 compared to $1.4 million for the fourth quarter of 2013, an increase of $4.0 million. This increase was primarily driven by professional fees incurred as a result of EPIRUS becoming a publicly traded company, headcount-related costs and non-cash stock compensation expenses. It also reflects an increase for BOW015 commercialization expenses.
  • Other income (expense) was $(0.2) million for the fourth quarter of 2014 compared to $(3.9) million for the fourth quarter of 2013, a decrease of $3.7 million. The decrease was primarily driven by lower interest expense related to convertible notes that were converted to equity in the first half of 2014.
  • The net loss for the fourth quarter of 2014 was $10.4 million, compared to a net loss of $7.8 million for the fourth quarter of 2013. 

Fiscal Year 2014 Financial Highlights

  • Cash and cash equivalents totaled $21.5 million at December 31, 2014. This does not include the public offering closed in February 2015, in which the Company raised approximately $52.8 million in gross proceeds.
  • R&D expenses increased to $16.3 million in 2014 from $9.7 million in 2013, an increase of $6.6 million. This increase was primarily the result of development, manufacturing and commercialization expenses related to BOW015, as well as the advancement of other pipeline products.     
  • G&A expenses increased to $23.0 million in 2014 from $4.8 million in 2013, an increase of $18.2 million. This increase was primarily driven by $5.8 million in merger-related professional fees and $1.8 million severance paid in connection with the merger. It also reflects operational costs associated with EPIRUS becoming a publicly traded company, commercial support costs for the BOW015 launch, as well as increased headcount and non-cash stock compensation expenses.
  • Other income (expense) was $(2.6) million in 2014 compared to $(6.3) million in 2013, a decrease of $3.7 million. The decrease was primarily driven by lower interest expense related to convertible notes that were converted to equity in the first half of 2014.  
  • The net loss for 2014 was $41.8 million compared to a net loss of $20.8 million for 2013. 

Conference Call and Webcast Information:

EPIRUS' leadership team will host a conference call and webcast tomorrow, March 24, 2015 at 10 a.m. Eastern Time, to discuss these financial results and recent corporate developments. To access the conference call, please dial 1-855-638-3957 (United States) or 1-224-633-1318 (International). The conference ID is 2890190. The webcast can be accessed on EPIRUS' website at http://ir.epirusbiopharma.com/index.cfm . Please connect to either the conference call or webcast at least 10 minutes early to ensure adequate time to register. The webcast will be archived on the Company's website for a period of three months.   

About EPIRUS Biopharmaceuticals

EPIRUS Biopharmaceuticals (Nasdaq: EPRS ) is a global biosimilar company focused on improving patient access to important medicines. EPIRUS' operationally synergistic pipeline of biosimilar product candidates includes BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab). The reference products for these candidates – Remicade, Humira® and Actemra®, respectively – together generated over $20 billion in global sales for 2013, according to EvaluatePharma®. EPIRUS has developed distinct strategies to access its targeted markets with the goal to build a profitable and sustainable biosimilar business. For more information visit our website at www.epirusbiopharma.com .   

Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release, including, but not limited to, statements relating to prospects for our product Infimab in India, plans for a global clinical program for BOW015, collaborations with Livzon, future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this document, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to EPIRUS or its management may identify forward-looking statements. EPIRUS cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by EPIRUS to secure and maintain relationships with collaborators and single-source contract manufacturers; risks relating to clinical trials; risks relating to the commercialization, if any, of EPIRUS' proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; risks related to the loss of any of EPIRUS' key management personnel; risks that EPIRUS may lack the financial resources and access to capital to fund proposed operations and other factors that are described in quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, which are available at http://www.sec.gov . There can be no assurance that the actual results or developments anticipated by EPIRUS will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, EPIRUS. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

The information in this release is provided only as of the date of this release, and EPIRUS undertakes no obligation or intention to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Financial Statements        
         
EPIRUS Biopharmaceuticals, Inc. 
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
         
  Three Months Ended December 31, Fiscal Year Ended December 31,
  2014 2013 2014 2013
Revenue  $ 4   $  -   $ 4   $ -  
         
Operating expenses:        
Research and development  4,798  2,431  16,286  9,659
General and administrative  5,362  1,399  22,973  4,809
Total operating expenses  10,160  3,830  39,259  14,468
Loss from operations  (10,156)  (3,830)  (39,255)  (14,468)
         
Other income (expense):        
Interest expense, net  (282)  (3,946)  (2,672)  (5,543)
Change in fair value of warrant liability  -   16  (222)  (789)
Other income and tax (expense), net  38  (11)  305  5
Total other income (expense)  (244)  (3,941)  (2,589)  (6,327)
Net loss  $ (10,400)  $ (7,771)  $ (41,844)  $ (20,795)
Net loss per share--basic and diluted  $ (0.80)  $ (32.79)  $ (6.81)  $ (88.26)
Weighted-average number of common shares used in net loss per share calculation--basic and diluted  12,920,843  237,026  6,141,605  235,603
 
EPIRUS Biopharmaceuticals, Inc. 
Condensed Consolidated Balance Sheets (Unaudited)
(In thousands)
     
  December 31,
2014
December 31,
2013
Assets    
Cash and cash equivalents  $ 21,462  $ 1,798
Prepaid expenses and other current assets  1,731  888
Property and equipment, net  704  90
In-process research and development  5,500  2,437
Intangible assets, net  3,605  - 
Goodwill  16,363  1,499
Other assets, noncurrent  2,024  82
Total assets  $ 51,389  $ 6,794
     
Liabilities and Stockholders' Equity (Deficit)    
Accounts payable and accrued expenses  $ 6,584  $ 3,559
Debt  7,282  - 
Deferred tax  2,904  923
Deferred revenue  996  - 
Other liabilities  1,222  - 
Convertible notes  -   12,500
Warrant liability  -   5,843
Convertible preferred stock  -   23,348
Stockholders' equity (deficit)  32,401  (39,379)
Total liabilities and stockholders' equity (deficit)  $ 51,389  $ 6,794

Remicade is a registered trademark of Johnson and Johnson ( www.jnj.com )

Humira is a registered trademark of AbbVie ( www.abbvie.com )

Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group ( www.gene.com )

Infimab is a registered trademark of Ranbaxy Laboratories ( www.ranbaxy.com )

EPIRUS Biopharmaceuticals, Inc. Jennifer Almond, +1-617-606-3288

Scroll down for more posts ▼

Top 10 Most Recent News Articles

University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 108

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 78

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 159

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading

Top 5 Most Recently Viewed Articles

Major Settlement Proposed for TD Mutual Fund Class Action Cases

Updated Category News Views 65

Understanding the TD Mutual Fund Class Action Settlement If you have ever held units of a TD Mutual Fund through a discount broker, you may be part of a significant class action settlement that has recently come to light. TD Asset Management Inc. has agreed to a settlement amounting to C$70.25 million aimed at resolving claims on behalf of individuals who have held units...

Continue Reading
The No-Nonsense Breakdown on Church & Dwight Co. Stocks

Updated Category News Views 192

Church & Dwight Co: The Lay of the Land Let’s be real. Church & Dwight Co Inc. (NYSE:CHD) is on the radar, trading at about $103.08, and it just popped a neat 1.46%. However, look a little deeper, and you see it’s been a rocky ride over the past year with a drop of 5.41%. Basically, it’s like gearing up for a race—only to find out you’re running on a rocky...

Continue Reading
Experience the Excitement of Jaialdi at Fairfield Inn & Suites

Updated Category News Views 256

Welcoming Guests to the Jaialdi Festival Fairfield Inn & Suites Boise West is thrilled to welcome visitors for the upcoming Jaialdi Festival, an extraordinary event that celebrates Basque culture and tradition. This festival is held once every five years and is expected to gather attendees from around the globe to participate in the festivities. The hotel, operated by...

Continue Reading
Viridien's Successful Senior Secured Notes Offering Explained

Updated Category News Views 137

Success in Senior Secured Notes Offering Today marked a significant achievement for Viridien S.A. as the company announced the successful pricing of its offering of US$450 million 10% senior secured notes and €475 million 8.5% senior secured notes, both maturing in 2030. This offering signals a strong confidence in Viridien's financial strategy and operational...

Continue Reading
Legal Insights: Investors of Ready Capital Corporation (RC) Act Now

Updated Category News Views 133

Understanding the Situation with Ready Capital Corporation (RC) As an investor in Ready Capital Corporation, it's essential to stay informed about recent developments regarding the company, especially if you've faced any financial losses. Currently, there's an important deadline approaching that could affect shareholders significantly. Key Dates and Details for Investors...

Continue Reading